Embecta Corp. Q1 FY2025 earnings call

1. Strategic Priorities: Focus on strengthening core business through brand transition and bolstering leadership in insulin injection devices; expanding product portfolio by leveraging manufacturing and commercial channel expertise; increasing financial flexibility through debt reduction and restructuring. 2. First Quarter Highlights: Generated $261.9 million in revenue, slightly exceeding internal expectations. Brand transition program on track, with phased execution starting in the second half of fiscal year 2025. Restructuring plan related to insulin patch pump program on track for completion by end of first half of fiscal year 2025. Updated financial guidance with adjusted operating and EBITDA margin guidance ranges raised, while maintaining adjusted earnings per share guidance range despite foreign exchange headwinds.

During the fiscal first quarter of 2025, Embecta Corp. generated $261.9 million in revenue, reflecting a 5.6% decline year-over-year on an as-reported basis or a 4.8% decline on an adjusted constant currency basis. Within the US, revenue for the quarter totaled $141.7 million, reflecting a year-over-year decline of 4.6% on an adjusted constant currency basis. International business revenue totaled $120.2 million, equating to a 5.1% decline on an adjusted currency basis as compared to the prior year period. By product family, pen needle revenue declined approximately 8.5%, syringe revenue declined approximately 4.2%, safety products grew approximately 11.3%, and contact manufacturing grew approximately 153%.

Updated revenue guidance: as-reported revenue expected to decline between 2.8% and 4.3%, resulting in a range of $1.075 billion to $1.092 billion. Adjusted gross margin guidance reaffirmed at 63.25% to 64.25%. Adjusted operating margin guidance raised to 29.5% to 30.5% from 29% to 30%. Adjusted EPS guidance range maintained. Constant currency revenue guidance unchanged.

Factors that could cause actual results to differ materially include foreign exchange rate fluctuations, which created a headwind of about 2.2%, and potential tariff changes that could impact global operations. Additionally, the impact of pillar two on the tax rate is a risk to consider.

Q: Walk through each of the key product categories and their performance expectations for the year, including pricing dynamics.

A: Pen needles comprise the majority, affected by factors like Q4 FY2024 distributor pulls and ERP implementations. Syringe category decline rates improving due to volume declines in US becoming smaller factor. Safety products grew due to competitor exit. Outlook for the year has lumpiness due to ERP implementations, with pen needles comprising majority of revenue.

Q: Capital allocation and M&A opportunism given debt pay down.

A: Focus on debt reduction with net leverage expected to be around 3 times by end of fiscal 2025, trending lower into 2026. M&A opportunistic but near term focus on debt repayment and separation programs, with more info on long-term margin progression at Analyst Day.

Q: Specific types of products for expanding product portfolio.

A: Products that can leverage commercial strength, such as in China for hospital sales, US for retail and payer relationships, Germany and Japan for endocrinologist channels. Details to be shared at Analyst Day in May 2025.